HEAL-4: Real-World Effectiveness of 4 Amniotic Allografts Adjunctive to Standard Care in DFU, VLU, and PU
NCT07223515
Cardiovascular Diseases, Diabetes Complications
Novi, Michigan, United States
View Trial DetailsNCT Number: NCT07223281
This observational study will evaluate the real-world effectiveness of four amniotic membrane-based products (Zenith™, Orion™, SurGraft FT™, Complete ACA™) in addition to standard care, compared with standard care alone. The study will use complete electronic health records (EHR) from multiple wound care centers across the United States (2022-2025) to generate study data for product-treated and propensity score-matched standard care cohorts for each product-indication combination. The overall study comprises 12 parallel sub-studies (one for each product-wound type combination), each aiming to answer whether adding the product improves healing outcomes versus standard care alone in that indication. The primary endpoint is the proportion of wounds achieving complete closure within 12 weeks, with subgroup analyses by wound severity measures, age groups, and number of product applications. Secondary outcomes are time-to-healing, early wound improvement (≥50% reduction in wound area by 4 weeks), wound-related complications, and subgroup analyses.
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Observational
Colorado Foot and Ankle, Colorado Springs, Colorado, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From index visit to 12 weeks post-index
Proportion of index wounds with 100% epithelialization, no drainage or dressings; confirmation on ≥1 follow-up within 60 days
Time frame: From index visit up to 24 months post-index
Time from the index visit to primary complete wound closure for wounds that heal during the study period
Time frame: From index visit to 4 weeks post-index
Proportion of patients whose wounds close greater than 50% within 4 weeks from the index visit
Time frame: From index visit up to 24 months post-index
Wound-related complications including infection requiring treatment, hospitalization, ED visits, and major or minor amputation
Legacy Medical Consultants
Industry
Real-World Effectiveness of Amniotic Membrane Allografts Versus Standard Wound Care in Chronic Wound Healing: A Multi-Site Study in Diabetic Foot Ulcers (DFU), Venous Leg Ulcers (VLU), and Pressure Ulcers (PU)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07223515
Cardiovascular Diseases, Diabetes Complications
Novi, Michigan, United States
View Trial DetailsNCT07078968
Cardiovascular Diseases, Diabetes Complications
Phoenix, Arizona, United States
View Trial DetailsNCT07541196
Arterial Ulcer, Cardiovascular Diseases
Ocoyoacac, State of Mexico, Mexico
View Trial DetailsNCT07375160
Cardiovascular Diseases, Diabetes Complications
View Trial Details